These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22481236)

  • 1. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners.
    Okamoto S; Kawamura K; Li Q; Yamanaka M; Yang S; Fukamachi T; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
    J Thorac Oncol; 2012 May; 7(5):873-82. PubMed ID: 22481236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
    Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M
    Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
    Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
    Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma.
    Jiang Y; Zhong B; Kawamura K; Morinaga T; Shingyoji M; Sekine I; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
    BMC Cancer; 2016 Jul; 16():455. PubMed ID: 27405588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
    Ory B; Blanchard F; Battaglia S; Gouin F; Rédini F; Heymann D
    Mol Pharmacol; 2007 Jan; 71(1):333-43. PubMed ID: 17050806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.
    Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Fukamachi T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
    PLoS One; 2013; 8(3):e60297. PubMed ID: 23555949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
    Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H
    Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes.
    Ohnuki H; Izumi K; Terada M; Saito T; Kato H; Suzuki A; Kawano Y; Nozawa-Inoue K; Takagi R; Maeda T
    Arch Oral Biol; 2012 Jul; 57(7):906-17. PubMed ID: 22172403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.
    Li Q; Kawamura K; Yamanaka M; Okamoto S; Yang S; Yamauchi S; Fukamachi T; Kobayashi H; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
    Cancer Gene Ther; 2012 Mar; 19(3):218-28. PubMed ID: 22223137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
    Li YY; Chang JW; Liu YC; Wang CH; Chang HJ; Tsai MC; Su SP; Yeh KY
    Anticancer Drugs; 2011 Jan; 22(1):89-98. PubMed ID: 20926944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid exerts antitumor effects in NB4 acute promyelocytic leukemia cells by inducing apoptosis and S phase arrest.
    Liu SS; Wang XP; Li XB; Liang JY; Liu LL; Lu Y; Zhong XY; Chen YX
    Biomed Pharmacother; 2014 Oct; 68(8):1031-6. PubMed ID: 25312823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
    Kuroda J; Kimura S; Segawa H; Sato K; Matsumoto S; Nogawa M; Yuasa T; Kobayashi Y; Yoshikawa T; Ottmann OG; Maekawa T
    Cancer Sci; 2004 Feb; 95(2):186-92. PubMed ID: 14965371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
    Guenther A; Gordon S; Tiemann M; Burger R; Bakker F; Green JR; Baum W; Roelofs AJ; Rogers MJ; Gramatzki M
    Int J Cancer; 2010 Jan; 126(1):239-46. PubMed ID: 19621390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E1B-55 kDa-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of anticancer agents.
    Yamanaka M; Tada Y; Kawamura K; Li Q; Okamoto S; Chai K; Yokoi S; Liang M; Fukamachi T; Kobayashi H; Yamaguchi N; Kitamura A; Shimada H; Hiroshima K; Takiguchi Y; Tatsumi K; Tagawa M
    J Thorac Oncol; 2012 Dec; 7(12):1850-1857. PubMed ID: 23154556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence.
    Shin J; Yang J; Lee JC; Baek KH
    Cell Signal; 2013 Dec; 25(12):2540-7. PubMed ID: 23993963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.
    Salaroglio IC; Campia I; Kopecka J; Gazzano E; Orecchia S; Ghigo D; Riganti C
    Oncotarget; 2015 Jan; 6(2):1128-42. PubMed ID: 25544757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells.
    Yang TY; Chang GC; Chen KC; Hung HW; Hsu KH; Sheu GT; Hsu SL
    Eur J Pharmacol; 2011 Aug; 663(1-3):17-26. PubMed ID: 21575631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.